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Five aromatic nitrogen-containing heterocycles, pyridazine (pydz, 1), pyrimidine (pm, 2), pyrazine (pz, 3),
quinoxaline (qx, 4) and phenazine (phz, 5) have been used for the synthesis of gold(III) and silver(I)
complexes. In contrast to the mononuclear Au1–5 complexes all having square-planar geometry, the
corresponding Ag1–5 complexes have been found to be polynuclear and of different geometries.
Complexes Au1–5 and Ag1–5, along with K[AuCl4], AgNO3 and N-heterocyclic ligands used for their
synthesis, were evaluated by in vitro antimicrobial studies against a panel of microbial strains that lead to
many skin and soft tissue, respiratory, wound and nosocomial infections. All tested complexes exhibited
excellent to good antibacterial activity with minimal inhibitory (MIC) values in the range of 2.5 to 100 mg
mL1 against the investigated strains. The complexes were particularly efficient against pathogenic
Pseudomonas aeruginosa (MIC ¼ 2.5–30 mg mL1) and had a marked ability to disrupt clinically relevant
biofilms of strains with high inherent resistance to antibiotics. Moreover, the Au1–4 and Ag1–5
complexes exhibited pronounced ability to competitively intercalate double stranded genomic DNA of P.
aeruginosa, which was demonstrated by gel electrophoresis techniques and supported by molecular
docking into the DNA major groove. Antiproliferative effect on the normal human lung fibroblast cell line
MRC5 has also been evaluated in order to determine therapeutic potential of Au1–5 and Ag1–5
complexes. Since the investigated gold(III) complexes showed much lower negative effects on the
viability of the MRC5 cell line than their silver(I) analogues and slightly lower antimicrobial activity against
the investigated strains, the combination approach to improve their pharmacological profiles was
applied. Synergistic antimicrobial effect and the selectivity index of 10 were achieved for the selected
gold(III)/silver(I) complexes mixtures, as well as higher P. aeruginosa PAO1 biofilm disruption activity, and
improved toxicity profile towards zebrafish embryos, in comparison to the single complexes. To the best
of our knowledge, this is the first report on synergistic activity of gold(III)/silver(I) complexes mixtures and
it could have an impact on development of new combination therapy methods for the treatment of
multi-resistant bacterial infections.Introduction
Metal-based drugs have a wide range of medicinal applications,
both as diagnostic and therapeutic agents, and are now, University of Kragujevac, R. Domanovića
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hemistry 2016routinely administered to patients.1,2 Generally, compounds
containing platinum (anticancer), silver (antimicrobial), iron
(antimalarial), bismuth (antiulcer), vanadium (antidiabetic)
and gold (antiarthritic) are examples of metal-based drugs
which have been used for the treatment of the wide range of
diseases.3 Although themechanism of biological action of metal
compounds for therapy and diagnosis has been extensively
investigated, in several cases is still not fully elucidated. The
activity of metal-based drugs usually relies on their redox
changes and/or ligand exchange reactions in vivo to generate the
active species.2,4 Metal complexes offer quite diverse chemistry



















































View Article Onlinefact that their properties can be modulated by the choice of the
metal oxidation state. Furthermore, the choice of the ligands
used for the synthesis of metal complexes allows tuning of their
lipophilicity, solubility and reactivity, which results in better
therapeutic activity against toxicity. The efforts to apply known
treatments or biological properties to new diseases are also
ongoing.5 In the metal-based therapeutic area, good examples
are development of antitumor agents from organotin complexes
that have been used as fungicides and antifouling agents, or
utilization of auranon, a clinically established antiarthritic
metallodrug as antimalarial, as well as evaluation of other
gold(I) and gold(III) complexes as potential antimicrobial
agents.2,6,7 Another option to further develop and/or improve
metal-based drugs would be to examine their potential in
a combination therapy, as dual therapeutics either by mixed
metal8,9 or mixed ligand10 approaches, or to fully exploit various
biological activities within the samemetal complex. At the same
time, growing evidence indicates that dual or combination
approaches or the development of safe and effective antimi-
crobials are urgently needed, especially in the case of infections
associated with critically ill patients.
Among other metals, gold and silver have attracted
numerous research efforts in terms of preparation of novel
coordination and organometallic compounds, which have been
evaluated as potential therapeutic agents.11 Gold(I) complexes
have been utilized for the treatment of rheumatoid arthritis and
a variety of rheumatic diseases from the middle of 20th century,
while a large number of gold(I) and gold(III) complexes have
been evaluated for their potential use in the treatment of
cancer, bronchial asthma, as anti-HIV and antimicrobial
agents.6,12 Silver and its various preparations have been applied
for the treatment of burns and wounds, venereal diseases,
abscesses, newborn conjunctivitis, in the last couple hundred
years, due to the antibacterial action of silver(I) ions.13 Following
the discovery of penicillin, the use of silver to treat bacteria
declined, however numerous applications of silver as an anti-
bacterial coating on surfaces of various medical and consumer
products have been developed and are currently used against
a range of pathogens such as Staphylococcus aureus, Pseudo-
monas aeruginosa and Escherichia coli.14,15 The antibacterial
mechanism of action of silver(I) ion has not been fully eluci-
dated, and more recently reports on the bacterial resistance to
known silver-basedmedicines are more frequent.16 On the other
hand, the development of novel silver(I) complexes, in which
silver(I) ion is chelated by the ligands specically tailored to
enhance solubility and pharmacokinetics is ongoing.1 Such
complexes may have a role in targeting pathogens associated
with chronic lung infections such as cystic brosis or cancer.1
An important class of ligands for the synthesis of biologically
active gold(III) and silver(I) complexes comprises of aromatic
nitrogen-containing heterocycles (N-heterocycles).17–20 These
compounds are of great importance in the coordination, bio-
inorganic and supramolecular chemistry and are oen found in
many natural products and biologically important mole-
cules.21–23 In the present study, ve N-heterocycles, pyridazine
(pydz, 1), pyrimidine (pm, 2), pyrazine (pz, 3), quinoxaline (qx,
4) and phenazine (phz, 5), were used as ligands for the synthesis13194 | RSC Adv., 2016, 6, 13193–13206of gold(III) and silver(I) complexes. Although the synthesis of
these complexes has been reported previously,24–30 their anti-
microbial and toxicological effects have not been investigated.
Considering this, in the present study, the in vitro antimicrobial
properties of the gold(III) and silver(I) complexes with the
abovementioned N-heterocycles were evaluated, as well as their
ability to combat difficult to treat bacterial biolms. The results
obtained from the antimicrobial evaluation of gold(III) and sil-
ver(I) complexes were compared to their cytotoxic and embry-
otoxic proles. The ability of the investigated complexes to
interact with bacterial genomic DNA (gDNA) has been evaluated
through in vitro and in silico approaches. Synergistic antimi-
crobial and improved toxicity prole was determined for the
mixtures of the selected silver(I) and gold(III) complexes.
Results and discussion
Synthesis and structural features of the gold(III) and silver(I)
complexes with nitrogen-containing heterocycles
In this study, ve N-heterocycles, pyridazine (pydz, 1), pyrimi-
dine (pm, 2), pyrazine (pz, 3), quinoxaline (qx, 4) and phenazine
(phz, 5), were used as ligands for the synthesis of gold(III) and
silver(I) complexes (Scheme 1).
Gold(III) complexes. Mononuclear gold(III) complexes of the
general formulae [AuCl3(N-heterocycle)], Au1–5, were prepared
from equimolar amounts of K[AuCl4] and the corresponding N-
heterocycle according to a procedure reported recently.24,25 The
structures of these complexes were also determined previously
by using NMR (1H and 13C NMR) and single-crystal X-ray
diffraction analysis.24,25 However, in the present study, the
stoichiometries of the investigated Au1–5 complexes were
conrmed by elemental microanalysis, and the structures
emerge from NMR (1H and 13C), IR and UV-vis spectroscopy (see
Experimental section). We found that spectroscopic data for
Au1–5 were in accordance with those reported previously for the
mononuclear gold(III) complexes with pydz, pm, pz, qx and phz
ligands, all containing one Au–N(heterocycle) and three Au–Cl
bonds in a square planar plane (Scheme 1).24,25
Silver(I) complexes. The silver(I) complexes Ag1–5 were
prepared in a high yield (>80%) by reacting AgNO3 with an
equimolar amount of the corresponding N-heterocyclic ligand
in ethanol by modication of the procedure reported in the
literature.26–30 The crystal structures of silver(I) complexes with
pydz, pm, pz, qx and phz were determined by single-crystal X-ray
diffraction analysis.26–30 In this study, we used NMR (1H and
13C), UV-vis and IR spectroscopic techniques for structural
characterization of Ag1–5 complexes (see Experimental section).
From the spectroscopic data, it was concluded that structures of
the investigated silver(I) complexes are in accordance with those
determined by X-ray analysis.26–30 Thus, in contrast to the
mononuclear N-heterocycle–gold(III) complexes Au1–5, all
having square planar coordination environment, the corre-
sponding silver(I) complexes Ag1–5 are polynuclear and have
different coordination geometries. A structural representation
of Ag1–5 complexes is given in Scheme 1. As can be seen, in Ag1
complex, Ag(I) ions are symmetrically bridged by pydz ligands,
while the remaining three coordination sites are occupied byThis journal is © The Royal Society of Chemistry 2016
Scheme 1 Structural representation of gold(III) (Au1–5) and silver(I)
(Ag1–5) complexes analyzed in this study (pydz ¼ pyridazine, pm ¼



















































View Article Onlinethe oxygen atoms from nitrate anions.27 On the other hand, the
Ag2 complex is a discrete tetracycle containing four Ag(I) ions
and four pm ligands, in which each Ag(I) ion has a bent coor-
dination geometry as a consequence of weak interaction with
two nitrate anions.29 Both complexes Ag3 and Ag4, containing
coordinated pz and qx, respectively, are 1D coordination poly-
mers with the characteristic linear two-coordination geometry
of Ag(I) ion,26,30 while the Ag5 complex has trigonal planar
geometry. The asymmetric unit of the latter complex comprises
Ag(I) ion, a nitrate and half of a phz molecule.28Stability of Au1–5 and Ag1–5 complexes
Solution stability. An essential prerequisite for the biological
evaluation of metal complexes is their sufficient stability in
solution.31,32 The solution behaviour of the Au1–5 and Ag1–5
complexes (Scheme 1) was analyzed by absorption UV-vis
spectrophotometry. For this purpose, the Au1–5 and Ag1–5
complexes were dissolved in DMF/H2O (1 : 1, v/v) and DMSO,This journal is © The Royal Society of Chemistry 2016respectively, and their UV-vis spectra were recorded directly
aer dissolution, as well as aer 24 h of incubation at 37 C.
Dimethyl sulfoxide was not used for the dissolution of Au1–5,
due to their decomposition to free aromatic N-heterocycles in
this solvent.24,25 On the other hand, all investigated silver(I)
complexes were stable in DMSO solution, i.e. no coordination of
this solvent to Ag(I) was observed during time based on the
proton NMR spectroscopy. The wavelengths of maximum
absorption for the Au1–5 and Ag1–5 complexes (lmax, nm), as
well as molar extinction coefficients (3, M1 cm1), determined
directly aer dissolution of the complexes in the corresponding
solvents, are listed in the Experimental section.
For most of the investigated gold(III) and silver(I) complexes,
the observed transitions remained substantially unmodied
over 24 h at 37 C, implying their stability in solution during
this time. Nevertheless, a slight decrease in the intensity of the
absorption maximumwas noticed, although without signicant
modications of spectrum shape. These minor changes might
be ascribed either to release of the N-heterocyclic ligand from
Au(III) and Ag(I) ions or to partial reduction of these ions to the
metallic gold and silver, respectively.33
Air/light stability. In addition to the sufficient solution
stability of the metal complexes evaluated as potential antimi-
crobial agents, their high air/light stability can be also of great
importance for their possible external application in the form of
ointments, gels and coating materials of dressings.34 In order to
investigate the air/light stability of the Au1–5 and Ag1–5
complexes, sterile cellulose discs impregnated with stock solu-
tion of these complexes (200 mg per disc, using 50 mg mL1
DMF and DMSO stock solution, respectively) were exposed to air
and light at 37 C and monitored within 96 h. The obtained
photos of the samples are presented in Fig. S1.† As can be seen,
Au1–5 clearly showed better air/light stability than the corre-
sponding Ag1–5 complexes. All investigated silver(I) complexes
became darker aer 24 h, whereas the corresponding gold(III)
complexes remained almost unaltered during this time, except
the complex Au5 containing phz, which started to be a little
beige in color. Moreover, the silver(I) complexes were almost
completely dark aer 96 h, except the Ag1 complex having
coordinated pydz ligand. On the other hand, the slow light
decomposition process was observed only for the Au5 complex.Antimicrobial and cytotoxic properties of Au1–5 and Ag1–5
complexes
Gold(III) complexes Au1–5 and the corresponding Ag1–5
complexes were evaluated as antibacterial agents against two
Gram-negative bacteria (Escherichia coli and Pseudomonas aer-
uginosa PAO1), two Gram-positive bacteria (Staphylococcus
aureus and Lysteria monocytogenes) and the fungus Candida
albicans (Table 1). All these microorganisms are human path-
ogens, which can cause and are associated with a variety of
diseases such as skin, wound and burn infections, pneumonia,
and infections of the central nervous system and urinary tract,
as well as with nosocomial infections and infections of critically
ill patients.35,36 The antimicrobial activity of Au1–5 and Ag1–5
and the starting compounds used for their synthesis, K[AuCl4]RSC Adv., 2016, 6, 13193–13206 | 13195
Table 1 Antimicrobial activities of Au1–5 and the corresponding Ag1–5 complexes in comparison to K[AuCl4] and AgNO3, respectively, as MIC












Au1 10  1 15.6  0.8 15.6  0.4 100  6 50  0.8
Ag1 2.5  0.1 7.8  0.4 15.6  0.4 7.8  0.6 7.8  0.5
Au2 15  1 15.6  0.8 15.6  0.5 100  8 200  3
Ag2 2.5  0.1 7.8  0.6 15.6  0.5 7.8  0.8 15.6  0.8
Au3 8  0.5 16  0.6 15.6  0.2 100  4 50  0.6
Ag3 7.8  0.5 15.6  0.8 15.6  0.2 7.8  0.4 15.6  0.6
Au4 12.5  0.5 31.2  0.4 15.6  0.5 100  4 250  1
Ag4 15.6  0.5 15.6  0.4 31.2  0.5 7.8  0.4 15.6  0.6
Au5 30  4 62.5  1 62.5  2 100  4 250  4
Ag5 7.8  4 15.6  1 31.2  2 15.6  0.4 31.2  0.9
K[AuCl4] 8  0.5 31.2  0.8 15.6  0.4 100  5 40  0.5



















































View Article Onlineand AgNO3, against the abovementioned strains is expressed as
minimal inhibitory concentration (MIC, mg mL1) and
compared to the effect on the viability on the human broblast
cell line (MRC5), to properly evaluate the therapeutic index
(Fig. 1).
The obtained results indicate that all tested gold(III) and
silver(I) complexes exhibited excellent to good antibacterial
activity against the investigated strains with MIC values in the
range of 2.5 to 100 mg mL1. None of the N-heterocyclic ligands
were toxic towards the bacterial strains in concentrations up to
250 mg mL1. Expectedly, silver(I) complexes showed moreFig. 1 In vitro antiproliferative effect of: (a) Au(III) complexes on human
fibroblasts following 48 h exposure at a range of concentrations ( –
10, – 50 and – 100 mg mL1); (b) Ag(I) complexes on human
fibroblasts following 48 h exposure at a range of concentrations ( – 1,
– 2 and – 5 mg mL1) and (c) calculated IC50 values against human
fibroblast cell line (MRC5).
13196 | RSC Adv., 2016, 6, 13193–13206potent antimicrobial properties in comparison to the corre-
sponding gold(III) complexes, except in the case of Au4 and S.
aureus (Table 1). The greatest difference was observable in the
case of L. monocytogenes with the MICs of silver(I) compounds
being generally 12.8-fold lower in comparison to the corre-
sponding gold(III) compounds.
Apart from the lower activity exhibited against L. mono-
cytogenes and C. albicans, Au(III) complexes showed considerable
activity against other bacterial strains with MIC values from 8 to
62.5 mg mL1. These values are quite comparable to the anti-
microbial activity of other organometallic gold(III) complexes
such as [AuCl2(ppy)] (ppy is 2-phenylpyridine),37 and compa-
rable or better than some gold(I) complexes containing N-
heterocyclic carbene ligands.6,38 The Au3 and Au1 exhibited
the highest antimicrobial activity, while Au5 was the least active
amongst all tested gold(III) complexes. From this, it can be
concluded that the antimicrobial activity of the tested gold(III)
complexes decreases with the increasing number of aromatic
rings in the N-heterocyclic ligands. The same was true for the
corresponding silver(I) complexes, i.e. Ag4 and Ag5 containing
bicyclic qx and tricyclic phz ligands, respectively, were slightly
less active in comparison to the diazine-containing silver(I)
complexes Ag1–3. The Ag1 and Ag2 exhibited similar antimi-
crobial activity prole with the pronounced activity against P.
aeruginosa and MIC values of 2.5 mg mL1. As can be seen from
Table 1, the antimicrobial activity of complexes was comparable
to that of K[AuCl4] and AgNO3. However, it is important to note
that the molar ratio of Ag(I) ion (n(Ag+)/Mr) in AgNO3 is
considerably higher than in the silver(I) complexes, i.e. 1.47,
1.76 and 1.53-fold higher than in Ag1–3, Ag4 and Ag5, respec-
tively. On the other hand, the difference in the molar ratio of
Au(III) ion is not signicant in the case of gold(III) complexes,
being 1.01, 1.15 and 1.28-fold higher in K[AuCl4] than in Au1–3,
Au4 and Au5, respectively.
The investigated Au(III) complexes exhibited much lower
negative effects on the viability of the normal human lung
broblast cell line MRC5 in comparison to Ag(I) complexes,
which is a desirable property for application of these
compounds as antibiotics (Fig. 1). In the case of the activityThis journal is © The Royal Society of Chemistry 2016
Fig. 2 Relative percentages showing biofilm disruption capabilities of
the (a) gold(III) and (b) silver(I) complexes( – P. aeruginosa PAO1
biofilm; – P. aeruginosa DM-49 biofilm). Relative percentages were
calculated upon comparing with the negative solvent vehicle control
(DMF and DMSO). Values presented are mean values of four replicates



















































View Article Onlineagainst P. aeruginosa PAO1, all Au(III) complexes exhibited
therapeutic index >3, with the best being 8 for Au3. All of the
tested Ag(I) compounds had negative therapeutic indexes, sug-
gesting that their activity should be further exploited in the
anticancer therapy or they can be used as antibiotics for external
applications. In addition, these complexes can be further
exploited in combination therapies and in infections closely
associated with critically ill patients with cancer. As it was found
previously, microorganisms and infections play major role in
carcinogenesis, as well as in antitumor response.35,39–41 Of the
12.7 million new cancer cases that occurred in 2008, around 2
million new cancer cases were attributable to the infections.39
Moreover, bacteremia is a major cause of life-threatening
complications in patients with cancer, that are more vulner-
able to invasive infection, due to ulcerative lesions in mucosal
surfaces, immune suppression, neutropenia, mucositis and the
use of invasive devices. Patients with cancer are also at
extremely high risk for infections caused by the antibiotic
resistant Gram-negative bacteria.35
According to the literature data, many silver(I) complexes
with N-heterocyclic compounds have a strong antibacterial
activity; however, their cytotoxicity has rarely been examined.
The cytotoxic activity of {[Ag(X)(phtz)]2(m-phtz)2} (X ¼ NO3,
CF3SO3
 and ClO4
), {[Ag(CF3SO3)(qz)]2}n and {[Ag(qz)][BF4]}n
against the human normal cell line MRC5 was moderate;
therefore, these complexes could be further evaluated as
possible antimicrobial agents.18 On the other hand, [Ag(NO3)
(qz)]n and {[Ag(CH3CN)]2(m-phtz)2}[BF4]2 exhibited a negative
effect on in vitro proliferation of the MRC5 cell line and also
toxicity on zebrash embryos, although signicantly lower than
that of AgNO3 and AgBF4 salts.42 Recently, Ortego et al.
synthesized and characterized (aminophosphine)gold(I) and
silver(I) complexes and evaluated them as antibacterial agents
against Gram-negative Salmonella enterica serovar typhimurium
and E. coli and Gram-positive L. monocytogenes and S. aureus.19
They have observed moderate antimicrobial activity for all
gold(I) complexes and the silver(I) derivatives without coordi-
nated PPh3 groups and suggested that the inhibition of pepti-
doglycan synthesis in the cell wall may be the mechanism of
action of these complexes because of their specic selectivity to
the Gram-positive versus Gram-negative bacteria. They also
highlighted the inuence of the donor atoms coordinated to the
metal center, however they did not examine cytotoxicity of these
complexes.19 On the other hand, the cytotoxicity of gold(III)
complexes towards MRC5 cell line has been previously exam-
ined, e.g. gold(III) complexes with the uoroquinolones anti-
microbial agents noroxacin, levooxacin and sparoxacin
have shown low cytotoxicity toward this cell line (IC50 values in
the range of 53–126 mM),43 as well as gold(III) complexes with
L-histidine-containing peptides (IC50 > 100 mM)24 and with esters
of (S,S)-ethylenediamine-N,N0-di-2-propanoic acid (IC50 ¼
23.15–97.88 mM).44
Especially good activity observed against clinically important
opportunistic pathogen P. aeruginosa PAO1, lead us to examine
antibacterial potential of Au(III) and Ag(I) complexes in more
detail. There are some recent reports that simple MIC testing
overlooks potential interaction of tested compounds withThis journal is © The Royal Society of Chemistry 2016serum proteins of the host,45 and therefore we have examined
the activity of the complexes in mammalian tissue culture
media supplemented with fetal bovine serum vs. standard
bacteriological media, and observed that serum does increase
MIC values generally two-fold (Table S1†). This phenomenon
does not occur in the case of Au3, Au5, Ag1 and Ag3–5
(Table S1†).
Biolms represent a major threat during infections, so the
ability to disrupt preformed biolms is highly desirable trait of
the novel antimicrobial agent. Indeed, all tested compounds
exhibited the ability to disrupt P. aeruginosa preformed biolms
using both ATCC and clinical isolate to different extent. Ag(I)
complexes were 2–3 fold more potent in dispersing biolms in
comparison to the corresponding Au(III) complexes, with Ag1
showing the best activity, followed by Ag4 and Ag5 (Fig. 2). On
the other hand, Au1 was able to disrupt P. aeruginosa PAO1
biolm to 15%, while it was not as good towards clinical isolate,
followed by Au2 with 60% disruption (Fig. 2a). All other Au(III)
complexes caused about 40% disruption of the preformed bio-
lms. Silver and silver-based compounds and materials have
previously been shown to be effective in combating persistent
and mature P. aeruginosa biolms, whereby the concentration
of silver(I) ions was found to be vital.46,47 On the other hand, this
is the rst report of the Au(III) complexes to be effective in the P.



















































View Article OnlineIn vitro DNA interaction ability using P. aeruginosa gDNA
DNA may be one of the primary targets of the examined
complexes, as transition metal complexes, including Au(III) and
Ag(I), are known to bind to DNA via both covalent and non-
covalent interactions.48,49 In covalent binding, the labile ligand
of a complex is replaced by a nitrogen base of DNA, such as
guanine N7. Non-covalent DNA interactions include inter-
calative, electrostatic and groove (surface) binding of cationic
metal complexes.50
The Ag1–4 and Ag1–5 complexes exhibited pronounced
ability to competitively intercalate double stranded bacterial
genomic DNA, which results in the inability of ethidium
bromide to intercalate and emit under UV exposure (Fig. 3a and
b). From the reduced emission intensity, visualized by gel
electrophoresis, the most stable intercalation occurred with Ag1
and Ag2, and Au1 and Au3 (85–100%), while other compounds
intercalated between 50% and 80% relative to the solvent
vehicle control (Fig. 3). The only complex that did not show this
ability was Au5 (Fig. 3a).
This is in line with a mechanistic study of the antibacterial
effect of silver(I) ions on E. coli and S. aureus, carried out by
electron microscopy combined with X-ray microanalysis using
AgNO3.51 That study suggested an antibacterial mechanism of
silver(I) through primary DNA interaction, which caused the
loss of its replication ability and a general inactivation of sulfur
containing proteins. On the other hand, it was suggested that
the mechanism of action of gold-based compounds is DNA-
independent, i.e. their interactions with DNA are not as tight
as those found for the isostructural platinum(II) complexes,52Fig. 3 In vitro interaction ability of (a) Au(III) and (b) Ag(I) complexes
with P. aeruginosa genomic DNA (results are considered significant
when compared to the solvent control, *p < 0.01); (c) computational
docking model illustrating interactions between DNA and all studied
complexes. Left – Au(III) complexes; Right – Ag(I) complexes.
13198 | RSC Adv., 2016, 6, 13193–13206and that gold–protein interactions are responsible for their
effects.53 Despite these facts, some gold(III) complexes, such as
those with terpyridine derivatives54 and [Au(Gly-L-His-N,N0,N00)
Cl]Cl$3H2O55 were found to target DNA in vitro.
DNA docking study.Molecular docking study was carried out
to gain information about in silico DNA binding affinity for the
studied gold(III) and silver(I) complexes. The predicted top-
ranking pose with the complex lowest energy was applied for
suggesting the best possible geometry of the complexes inside
the DNA double helix and the highest binding affinity of DNA.
MolDock score, docking score, Rerank score, Hbond score, van
der Waals (vdW) score, steric interactions, vdW, Hbond and
NonHBond interaction with DNA and ligand efficiency (LE)
were used for evaluating interactions of complexes with DNA.
Top ranked poses according to the used scoring functions are
presented in Table 2.
The more negative the relative binding energy, greater the
binding propensity of the complex with DNA, which can be
correlated with the obtained experimental values for antibac-
terial activity. According to the obtained results for van der
Waals interaction of complexes with DNA, among the studied
gold(III) complexes the highest interaction energy has Au1
(811.422 kcal mol1), followed by Au3 (810.903 kcal mol1)
and Au2 (751.458 kcal mol1) and the lowest interaction was
determined for Au5 (15.804 kcal mol1). All obtained results
are in good correlation with the presented experimental results
for MIC values and with their in vitro DNA intercalation ability.
Furthermore, the obtained results for silver(I) complexes
revealed that highest interaction energy has Ag1 (605.265 kcal
mol1), followed by Ag4 (275.394 kcal mol1) and Ag2
(169.154 kcal mol1) and the lowest interaction was deter-
mined for Ag3 (126.827 kcal mol1). Like for gold(III)
complexes, the obtained results for silver(I) complexes are in
good correlation with the presented experimental results for
MIC values and with their in vitro DNA intercalation ability.
Hydrogen bonds formed between complex and DNA are
important for metal complex DNA binding and for further
possible antibacterial activity.56,57 According to Hbond values,
gold(III) complexes have higher interaction energies in
comparison to silver(I) complexes. Also docking studies deter-
mined that Ag1 and Ag4 do not form hydrogen bonds with DNA.
The best poses for all studied complexes according to their
values for van der Waals interaction with DNA are presented in
Fig. 3c. The best docking pose for each studied complex indi-
vidually is presented in Fig. S2 and S3.† The minimum energy
docked pose revealed that all complexes are very well tted into
the DNA major groove. Docking poses suggest that complexes
and DNA base pairs are arranged in such way that they have
effective p–p stacking interactions. These interactions can lead
to higher van der Waals interaction with the DNA functional
groups which dene the stability of groove making the AT
regions more preferable regions of dodecamer.58 The investi-
gated complexes exhibited additional stabilization through the
strong intermolecular hydrogen bonding interaction between
the C-2 carbonyl oxygen of T and the N-3 nitrogen of A. The best
binding pose in the AT stretches of the minor groove was
indicative of an extensive H-bonding network.This journal is © The Royal Society of Chemistry 2016
Table 2 Score values (kcal mol1) for the studied complexesa
Complex DNA (vdW) DNA (HBond) HBond LE NonHBond Rerank score Steric MolDock score vdW
Au1 811.422 689.656 689.656 470.791 677.271 470.791 322.841 689.656 642.738
Au2 751.458 736.434 736.434 520.097 719.698 520.097 353.742 736.434 672.067
Au3 810.903 686.213 686.213 452.296 652.646 452.296 31.877 686.213 467.109
Au4 111.608 903.312 645.223 426.731 845.864 597.424 416.882 903.312 693.482
Au5 15.804 106.409 591.159 313.318 985.353 563.972 558.592 106.409 173.122
Ag1 605.265 296.744 0 539.949 0 662.647 483.895 105.993 117.505
Ag2 169.154 108.521 376.019 683.749 575.489 626.223 372.743 922.174 669.465
Ag3 126.827 647.899 351.878 683.425 45.974 644.819 450.744 844.333 140.206
Ag4 275.394 542.692 0 627.147 0 907.038 550.965 135.937 189.769
Ag5 137.184 209.286 340.886 585.522 488.906 556.015 245.512 164.789 510.428



















































View Article OnlineSynergistic effect of Au(III) and Ag(I) complexes
Clinicians oen resort to combination therapy as a conse-
quence of difficult-to-treat multi-resistant bacterial infections
and or combination of diseases.59,60 Synergistic effects are oen
observable when combining antibiotics with different mode of
action, such in the case of azithromycin and cationic antimi-
crobial peptides, that were effective against multidrug-resistant
Gram-negative bacterial pathogens.45 Furthermore, nanosilver
preparations were found to synergise in activity with chlorhex-
idine, resulting in bactericidal action towards two opportunistic
wound pathogenic bacteria, P. aeruginosa and Staphylococcus
epidermidis,61 while silver present in wound-dressing made
bacteria more susceptible to the activity of antibiotics.47 More
recently, synergy of silver nanoparticles and aztreonam against
P. aeruginosa PAO1 biolms was also reported.62
Prompted by these ndings, we decided to test whether Ag1
as the most potent antimicrobial complex (Table 1) would have
the synergistic effect on the activity of Au1 or Au3. Although Ag1
was less active toward the investigated bacterial strains than
AgNO3, this silver(I) complex was less toxic on the normal
human lung broblast cell line MRC5 (Table 1) and also on
zebrash embryos (Table 3; vide infra) than the silver(I) salt.
Moreover, Ag1 was much more potent in disrupting the per-
formed biolms of P. aeruginosa strains in comparison to
AgNO3 (Fig. 2). Due to the fact that the biological effect of
complexes depends on the dissolution dynamics, we reasoned
that mixing two complexes would be more suitable than
complex and a salt. Considering these facts, we decided toTable 3 LC50 values (mg mL
1) as derived from the concentration–
response curves for gold(III) and silver(I) complexes and their mixtures
in zebrafish toxicity assay at 114 hpf





Au3/Ag1 6.4 : 1 13.66
Au1/Ag1 8 : 1 23.74
Au1 24.25
K[AuCl4] 46.98
This journal is © The Royal Society of Chemistry 2016choose Ag1 complex instead of AgNO3. Using microdilution
checkerboard method, we have shown that quarter of the MIC
concentration of Ag1 reduced theMIC of Au1 and Au3 by half, to
5 mg mL1 and 4 mg mL1 respectively. Half MIC concentration
of Ag1 (1.2 mg mL1) reduced MIC of Au3 four times (to 2 mg
mL1). Based on the calculated fractional inhibitory concen-
tration index of 0.75 for both mixtures containing Ag1, syner-
gistic antimicrobial effect was conrmed (Fig. 4a), and we have
decided to test two mixtures, Au1/Ag1 (8 : 1) and Au3/Ag1
(6.4 : 1), for P. aeruginosa antibiolm activity, cytotoxicity and
embryotoxicity. Both mixtures were conrmed to be able to
efficiently disrupt preformed biolms of P. aeruginosa PAO1,
when used in MIC concentrations (Fig. S4†), while their cyto-
toxic prole was much improved in comparison to Ag1 (Fig. 4b).
IC50 values of the mixtures were 50 mg mL
1 and 55 mg mL1 for
Au1/Ag1 (8 : 1) and Au3/Ag1 (6.4 : 1) respectively, which
improved selectivity index to >10. Furthermore, lower concen-
trations (2–25 mg mL1) of both mixtures did not affect cell
morphology (Fig. 4c). Using this approach, we have conrmed
that the antimicrobial synergies exist in the combination of
silver(I) and gold(III) complexes, with the combined effects being
greater than the sum of the individual effects, and that these
synergies may be particularly effective in the treatment of
biolm-mediated infections. More importantly, toxicity was
also modulated in a favorable manner.
The early study of Rhodes et al. also observed that copper(II)
compounds and aurothiomalate were synergistic in their
growth inhibitory effects towards Pseudomonas putida strains.63
However, to the best of our knowledge, there is no literature
data on synergistic effects of the Au(III) and Ag(I) complexes.
This may be due to the different mode of action or differential
uptake mechanism of these two metal complexes. Based on
these results it would be of interest to generate and assess
dinuclear Au–Ag complexes.Embryotoxicity of the selected Au(III) and Ag(I) complexes and
their mixtures
In order to investigate in vivo toxicity of the selected gold(III) and
silver(I) complexes and their mixtures, we used zebrash
embryos and followed their survival and development upon the
treatments with these compounds. Zebrash are frequentlyRSC Adv., 2016, 6, 13193–13206 | 13199
Fig. 4 Antimicrobial and cytotoxic profile of the investigated mixtures
of gold(III) and silver(I) complexes in comparison to the single
complexes. (a) MIC concentrations against P. aeruginosa PAO1
determined inmicrodilution broth assay; (b) MTT assay using ( – 2, –
10, – 25 and – 50 mg mL1); and (c) morphological appearance of




















































View Article Onlineused as in vivo vertebrate model for drug discovery and safety
evaluation of pharmacologically active compounds due to their
signicant genetic similarity and very good correlation with
humans in response to pharmaceuticals.64,65 Also, their body
transparency offers the possibility for visual inspection of all
inner organs development upon applied treatments. As zebra-
sh embryos are normally hatched by 72 hours post fertilization
(hpf),66 and some bioactive compound may impede this process
and consequently reduce embryos' survival, the embryos
development in this study was examined up to 114 hpf.
Obtained in vivo results revealed different toxicity proling of
the tested mixtures in response to their complexes (Table 3 and
Fig. 5). While gold(III) and silver(I) complexes showed dose- and
time-dependent mortality on zebrash embryos, as well as
teratogenic inuences at each tested concentration, both Au/Ag
mixtures exerted only dose-dependent toxicity without terato-
genicity signs at embryos that were alive. Based on LC50 values
(Table 3), these compounds are ranked by their toxicity: AgNO3
> Ag1 > Au3 > Au3/Ag1 6.4 : 1 > Au1/Ag1 8 : 1 > Au1 > K[AuCl4].
None embryos survived at 50 mg mL1 of any of the tested
compounds. The treatment with 10–25 mg mL1 of complex Au3
prevented hatching of all alive zebrash embryos, resulting in13200 | RSC Adv., 2016, 6, 13193–13206mortality of majority of them during period from 96 to 114 hpf
(Fig. 5a). Otherwise, hatching process is primarily biochemical
process driven by Zn-metalloproteases, which function may be
disrupted by chemical stress.67 As control embryos hatched up
to 72 hpf, the prevention of embryos hatching under Au3
treatment was probably achieved by inhibition of the hatching
enzymes, since alive embryos stayed unhatched up to 114 hpf.
Recently, Lin et al. demonstrated that some free metal ions
released frommetal-oxide nanoparticles could bind to enzyme's
active site and thus inhibited metalloprotease activity and
hatching success.68
All alive embryos upon the exposure to Ag1 complex devel-
oped serious skeletal abnormalities (scoliosis, smaller head, jaw
deformities; Fig. 5b), while embryos treated with Au1 complex
at concentrations higher than 5 mg mL1 showed heartbeat
disturbance, with signicantly increased heartbeat rate (data
not shown). However, Au1 was the least toxic metal complex
tested on zebrash, with LC50 value of 24.25 mg mL
1 (Table 3).
Importantly, the mixtures Au1/Ag1 8 : 1 and Au3/Ag1 6.4 : 1,
which showed higher antimicrobial bioactivity then tested
complexes on their own (Fig. 4a) and improved cytotoxicity
prole (Fig. 4b), did not show any adverse effect on embryos'
development, heartbeat rate and hatching (Fig. 5b). The
embryos treated with AgNO3, which was used for the synthesis
of silver(I) complexes, had lethal outcome at each tested
concentration up to 114 hpf, whereas alive embryos (4%) have
only been detected upon treatment with 5 mg mL1, and were
seriously teratogenic (Table S2†). Results obtained upon AgNO3
exposure are in line with the literature data, where low dose of
AgNO3 were documented to be lethal for zebrash embryos.69
On the other hand, K[AuCl4], which was used for the synthesis
of gold(III) complexes and is not being used in the clinical
practice, exerted low toxicity on zebrash embryos (Table S2†),
as well as low in vitro cytotoxic activity. The literature data on
embryotoxicity of gold(III) complexes is limited, but previous
studies did show that [N-(N0,N0-dimethylaminoethyl)-1,8-naph-
thalimide-4-sulde](triethylphosphine)gold(I) complex can
possess signicant anti-angiogenic potential in the develop-
ment of zebrash embryos.70Experimental
Materials
Distilled water was demineralized and puried to a resistance of
greater than 10 MU.cm1. Potassium tetrachloridoaurate(III)
(K[AuCl4]), silver(I) nitrate (AgNO3) pyridazine, pyrimidine,
pyrazine, quinoxaline, phenazine, ethanol, acetonitrile
dichloromethane, deuterated acetone and dimethyl sulfoxide
were purchased from the Sigma-Aldrich. All the employed
chemicals were of analytical reagent grade and used without
further purication.Synthesis of the gold(III) and silver(I) complexes with aromatic
N-heterocycles
Gold(III) and silver(I) complexes with aromatic N-heterocycles,
pyridazine (pydz, 1), pyrimidine (pm, 2), pyrazine (pz, 3),This journal is © The Royal Society of Chemistry 2016
Fig. 5 Comparison of toxicity of silver(I) complex (Ag1) and gold(III) complexes (Au1 and Au3) with their two mixtures (Au1/Ag1 8 : 1 and Au3/Ag1
6.4 : 1) on development of zebrafish embryos after 114 hpf exposure to the different concentrations. (a) Embryo distribution: – normal and
hatched embryos, – embryos died up to 96 hpf, – unhatched larvae which dead in period from 96 hpf to 114 hpf, and – teratogenic
embryos. (b) Images of zebrafish embryos at 114 hpf after the treatments with gold(III) and silver(I) complexes and their mixtures. Embryos treated
with: 5 mgmL1 of Ag1 had scoliosis, head and snout deformations; 25 mgmL1 of Au3were prevented for hatching andmostly died up to 114 hpf;



















































View Article Onlinequinoxaline (qx, 4) and phenazine (phz, 5), were synthesized by
modication of the previously described methods.24–27
Gold(III) complexes (Au1–5). The solution of 0.25mmol of the
corresponding aromatic N-heterocycles, 18.5 mL of 98% pydz,
19.9 mL of 99% pm, 20.0 mg of pz, 32.5 mg of qx and 45.0 mg of
phz in 1.0 mL of ethanol was added slowly under stirring to the
solution containing an equimolar amount of K[AuCl4] (94.5 mg
in 5.0 mL of water). The yellow precipitate, formed immediately
aer addition of the N-heterocyclic ligand, was ltered off,
washed with water, and recrystallized in dichloromethane to
form yellow crystals of gold(III) complexes. The crystals were
collected from the solution and dried in the dark at ambient
temperature. The yield was 92% for [AuCl3(pydz)] (Au1) (88.2
mg), 83% for [AuCl3(pm)] (Au2) (79.6 mg), 85% for [AuCl3(pz)]
(Au3) (81.5 mg), 65% for [AuCl3(qx)] (Au4) (70.4 mg) and 89% for
[AuCl3(phz)] (Au5) (107.6 mg). All complexes were pure based on
elemental microanalysis and NMR (1H and 13C) spectroscopy.
The obtained NMR spectroscopic results were in accordance
with those previously reported for the same complexes.24,25
Anal. calcd for Au1¼ C4H4AuCl3N2 (Mr ¼ 383.41): C, 12.53%;
H, 1.05%; N, 7.31%. Found: C, 12.87%; H, 1.21%; N, 7.57%. 1H
NMR (400 MHz, CD3COCD3): d ¼ 8.45 (ddd, J ¼ 8.2, 4.9, 1.5 Hz,
1H), 8.60 (ddd, J¼ 8.2, 5.7, 2.1 Hz, 1H), 9.51 (ddd, J¼ 4.9, 2.1, 1.0
Hz, 1H), 9.92 ppm (ddd, J ¼ 5.7, 1.5, 1.0 Hz, 1H). 13C NMR (101
MHz, CD3COCD3): d¼ 135.1, 136.5, 156.5, 156.6 ppm. IR (KBr, n,
cm1): 3430(br), 3093(m), 3081(m), 1632(m), 1567(m), 1455(m),
1398(vs.), 1299(m), 1221(w), 1153(w), 1058(w), 975(s), 774(vs.),
727(m), 687(w), 642(w), 472(w). UV-vis (DMF/H2O, lmax, nm):
298.0 (3 ¼ 6.9  102 M1 cm1).
Anal. calcd for Au2¼ C4H4AuCl3N2 (Mr ¼ 383.41): C, 12.53%;
H, 1.05%; N, 7.31%. Found: C, 12.96%; H, 1.14%; N, 7.13%. 1HThis journal is © The Royal Society of Chemistry 2016NMR (400 MHz, CD3COCD3): d ¼ 8.19 (ddd, J ¼ 6.1, 4.9, 1.1 Hz,
1H), 9.32 (dd, J ¼ 4.9, 2.0 Hz, 1H), 9.51 (ddd, J ¼ 6.1, 2.0, 1.3 Hz,
1H), 9.79 ppm (brs, 1H). 13C NMR (101 MHz, CD3COCD3): d ¼
125.2, 157.6, 158.0, 162.6 ppm. IR (KBr, n, cm1): 3437(br),
3095(m), 3070(m), 1637(w), 1591(s), 1552(m), 1465(m),
1412(vs.), 1177(w), 1133(w), 1084(w), 1062(m), 951(w), 819(m),
693(s), 641(m), 472(w). UV-vis (DMF/H2O, lmax, nm): 296.0 (3 ¼
6.4  102 M1 cm1).
Anal. calcd for Au3¼ C4H4AuCl3N2 (Mr ¼ 383.41): C, 12.53%;
H, 1.05%; N, 7.31%. Found: C, 12.69%; H, 1.12%; N, 7.15%. 1H
NMR (400 MHz, CD3COCD3): d ¼ 9.30 ppm (AA0BB0, 4H). 13C
NMR (101 MHz, CD3COCD3): d ¼ 145.0, 151.2 ppm. IR (KBr, n,
cm1): 3446(br), 3121(m), 3104(m), 1636(w), 1584(w), 1417(vs.),
1225(w), 1167(m), 1122(m), 1073(m), 1015(w), 798(s), 725(w),
472(m). UV-vis (DMF/H2O, lmax, nm): 296.0 (3 ¼ 1.0  103 M1
cm1).
Anal. calcd for Au4¼ C8H6AuCl3N2 (Mr ¼ 433.46): C, 22.17%;
H, 1.40%; N, 6.46%. Found: C, 22.45%; H, 1.58%; N, 6.49%. 1H
NMR (400 MHz, CD3COCD3): d ¼ 8.27 (ddd, J ¼ 8.2, 7.1, 1.2 Hz,
1H), 8.38 (ddd, J¼ 8.6, 7.1, 1.4 Hz, 1H), 8.48 (ddd, J¼ 8.2, 1.4, 0.7
Hz, 1H), 8.90 (ddd, J ¼ 8.6, 1.2, 0.7 Hz, 1H), 9.57 (d, J ¼ 2.7 Hz,
1H), 9.84 ppm (d, J ¼ 2.7 Hz, 1H). 13C NMR (101 MHz, CD3-
COCD3): d¼ 127.2, 131.5, 134.2, 135.5, 137.5, 147.1, 147.8, 149.5
ppm. IR (KBr, n, cm1): 3400(br), 3064(w), 1610(w), 1579(w),
1500(vs.), 1465(m), 1423(w), 1384(w), 1355(vs.), 1293(w),
1269(w), 1220(m), 1207(m), 1147(m), 1136(m), 1045(m), 971(m),
870(s), 849(m), 780(m), 752(s), 654(w), 538(w), 530(w). UV-vis
(DMF/H2O, lmax, nm): 316.0 (3 ¼ 2.1  103 M1 cm1).
Anal. calcd for Au5 ¼ C12H8AuCl3N2 (Mr ¼ 483.52): C,
29.81%; H, 1.67%; N, 5.79%. Found: C, 30.02%; H, 1.60%; N,



















































View Article Online6.8, 1.1 Hz, 2H), 8.58 (ddd, J¼ 8.9, 6.8, 1.3 Hz, 2H), 8.65 (ddd, J¼
8.7, 1.3, 0.6 Hz, 2H), 9.19 ppm (ddd, J ¼ 8.9, 1.1, 0.6 Hz, 2H). 13C
NMR (101 MHz, CD3COCD3): d ¼ 126.1, 131.9, 133.5, 138.4,
147.5 ppm. IR (KBr, n, cm1): 3435(br), 3053(w), 2923(w),
2852(w), 1618(w), 1598(w), 1521(m), 1470(s), 1432(m), 1384(w),
1352(m), 1285(w), 1230(w), 1173(w), 1127(s), 836(m), 749(vs.),
662(w), 594(s), 524(w). UV-vis (DMF/H2O, lmax, nm): 368.0 (3 ¼
4.4  102 M1 cm1).
Silver(I) complexes (Ag1–5). The solution of 2.0 mmol of
AgNO3 (339.7 mg) in 5.0 mL of ethanol was added slowly under
stirring to the solution containing an equimolar amount of the
corresponding N-heterocycle (148.2 mL of 98% pydz, 159.2 mL of
99% pm, 160.2 mg of pz, 260.3 mg of qx and 360.4 mg of phz)
dissolved in 20.0 mL of warm ethanol. The reaction mixture was
stirred in the dark at room temperature for 3 h. The solid
product of Ag1–5 complexes precipitated during this time was
ltered off and dissolved in 20.0 mL of acetonitrile. The
complexes were crystallized aer acetonitrile solutions were le
to stand in the refrigerator at +4 C for four days. The colorless
crystals of Ag1–4 and yellow crystals of Ag5 were collected from
the solution and dried in the dark at ambient temperature.
Yield: 440.0 mg (88%) for {[Ag(NO3)]2(m-pydz)2}n (Ag1), 399.9 mg
(80%) for {[Ag(pm)](NO3)}n (Ag2), 419.9 mg (84%) for
{[Ag(pz)](NO3)}n (Ag3), 468.0 mg (78%) for {[Ag(qz)](NO3)}n (Ag4)
and 462.7 mg (89%) for {[Ag(NO3)]2(m-phz)}n (Ag5). All
complexes were pure based on elemental microanalysis and
NMR (1H and 13C) spectroscopy.
Anal. calcd for Ag1 ¼ C4H4AgN3O3 (Mr ¼ 249.96): C, 19.22%;
H, 1.61%; N, 16.81%. Found: C, 19.26%; H, 1.76%; N, 17.03%.
1H NMR (200 MHz, DMSO): d ¼ 7.76 (dd, J ¼ 3.8, 3.2 Hz, 2H),
9.25 ppm (dd, J ¼ 3.8, 3.2 Hz, 2H). 13C NMR (50 MHz, DMSO):
d ¼ 127.6, 152.4 ppm. IR (KBr, n, cm1): 3430(br), 3059(m),
1646(w), 1570(m), 1414(vs.), 1384(vs.), 1286(m), 1122(w),
1084(w), 1063(m), 966(m), 825(m), 761(m), 717(w), 667(m),
626(w). UV-vis (DMSO, lmax, nm): 322.0 (3 ¼ 3.1  102 M1
cm1).
Anal. calcd for Ag2 ¼ C4H4AgN3O3 (Mr ¼ 249.96): C, 19.22%;
H, 1.61%; N, 16.81%. Found: C, 19.18%; H, 1.62%; N, 17.10%.
1H NMR (200 MHz, DMSO): d ¼ 7.58 (td, J ¼ 5.0, 1.5 Hz, 1H),
8.78–8.88 (m, 2H), 9.20 ppm (s, 1H). 13C NMR (50 MHz, DMSO):
d ¼ 122.3, 157.5, 158.8 ppm. IR (KBr, n, cm1): 3480(br),
3085(m), 1763(w), 1571(s), 1399(vs.), 1383(vs.), 1226(m),
1177(w), 1160(w), 1067(w), 825(s), 720(m), 647(w), 625(w). UV-vis
(DMSO, lmax, nm): 294.0 (3 ¼ 2.2  102 M1 cm1).
Anal. calcd for Ag3 ¼ C4H4AgN3O3 (Mr ¼ 249.96): C, 19.22%;
H, 1.61%; N, 16.81%. Found: C, 19.16%; H, 1.61%; N, 17.11%.
1H NMR (200 MHz, DMSO): d ¼ 8.67 ppm (s, 4H). 13C NMR (50
MHz, DMSO): d ¼ 145.4 ppm. IR (KBr, n, cm1): 3445(br),
3082(w), 3045(w), 1494(w), 1384(vs.), 1154(m), 1132(w), 1081(w),
1054(m), 1023(m), 990(w), 825(m), 805(m). UV-vis (DMSO, lmax,
nm): 320.0 (3 ¼ 4.3  102 M1 cm1).
Anal. calcd for Ag4 ¼ C8H6AgN3O3 (Mr ¼ 300.02): C, 32.03%;
H, 2.02%; N, 14.01%. Found: C, 32.02%; H, 2.07%; N, 14.21%.
1H NMR (200 MHz, DMSO): d¼ 7.84–7.94 (m, 2H), 8.07–8.18 (m,
2H), 8.97 ppm (s, 2H). 13C NMR (50 MHz, DMSO): d ¼ 129.3,
130.4, 142.4, 145.9 ppm. IR (KBr, n, cm1): 3611(br), 3080(w),
3048(w), 3015(w), 1767(w), 1738(w), 1629(w), 1611(w), 1582(w),13202 | RSC Adv., 2016, 6, 13193–132061498(m), 1457(w), 1421(m), 1384(vs.), 1361(vs.), 1307(m),
1206(m), 1138(m), 1125(m), 1070(w), 1038(m), 954(m), 868(m),
850(m), 767(m), 756(m), 716(m), 659(w), 628(w), 609(w), 535(w),
513(w). UV-vis (DMSO, lmax, nm): 316.0 (3 ¼ 3.1  103 M1
cm1).
Anal. calcd for Ag5 ¼ C12H8Ag2N4O6 (Mr ¼ 519.95): C,
27.72%; H, 1.55%; N, 10.78%. Found: C, 27.92%; H, 1.65%; N,
10.55%. 1H NMR (200MHz, DMSO): d¼ 7.92–8.04 (m, 4H), 8.23–
8.35 ppm (m, 4H). 13C NMR (50 MHz, DMSO): d ¼ 129.5, 131.3,
143.0 ppm. IR (KBr, n, cm1): 3678(br), 3059(w), 3009(w),
1516(m), 1472(w), 1419(s), 1384(vs.), 1361(s), 1297(vs.), 1209(m),
1167(w), 1152(m), 1119(m), 1063(w), 1029(m), 1002(w), 977(w),
953(w), 906(w), 863(w), 828(m), 791(w), 745(s), 660(w), 596(m),
552(w), 528(w), 502(w), 480(w), 459(w). UV-vis (DMSO, lmax, nm):
366.0 (3 ¼ 7.7  103 M1 cm1).
Measurements
Elemental analyses for carbon, hydrogen and nitrogen of the
synthesized gold(III) and silver(I) complexes were performed by
the Microanalytical Laboratory, Faculty of Chemistry, University
of Belgrade. NMR spectra of gold(III) complexes Au1–5 were
recorded at 25 C in CD3COCD3 on a Bruker Avance III 400 MHz
spectrometer (1H at 400 MHz, 13C at 101 MHz), equipped with
a 5 mm dual 13C/1H probe head, while those of silver(I)
complexes Ag1–5were recorded in DMSO-d6 on a Varian Gemini
2000 spectrometer (1H at 200 MHz, 13C at 50 MHz). Chemical
shis are reported in parts per million (ppm) and scalar
couplings are reported in hertz. 10 mg of each complex was
dissolved in 0.7 mL of the corresponding solvent, and this
solution was transferred into a 5 mm NMR tube. It is important
to note that Au1–5 are unstable in DMSO solvent and readily
undergo decomposition to yield free diazaaromatic
compounds.24,25 This problem oen occurs for Au(III) chloride–
azine complexes and should be always taken into account when
working with this solvent.71,72 Infrared spectra were recorded as
KBr pellets on a Perkin Elmer Spectrum One spectrometer over
the range of 450–4000 cm1. The UV-vis spectra were recorded
on a Cary 100 spectrophotometer (Varian, USA), aer dissolving
the corresponding gold(III) and silver(I) complex in DMF/H2O
(1 : 1, v/v) mixture and DMSO, respectively, as well as aer 24 h
of incubation in the dark at 37 C, over the wavelength range of
200–600 nm. The concentration of the gold(III) and silver(I)
complexes was 0.50 and 0.25 mg mL1, respectively.
Air/light stability of gold(III) and silver(I) complexes
The air/light stability of the gold(III) complexes Au1–5 and the
corresponding silver(I) complexes Ag1–5 was studied by indirect
light in air atmosphere at room temperature. Sterile cellulose
discs were impregnated with the gold(III) and silver(I) complexes
(200 mg per disc, using 50 mg mL1 DMF and DMSO stock
solution, respectively) and exposed to air and light. The stability
was monitored visually within 96 h.
Antimicrobial and cytotoxicity studies
Minimal inhibitory concentrations (MIC) of Au(III) and Ag(I)



















































View Article Onlinecompounds, were determined according to the standard broth
microdilution assays, recommended by the National
Committee for Clinical Laboratory Standards (M07-A8) for
bacteria and Standards of European Committee on Antimicro-
bial Susceptibility Testing (EDef7.1.). The tested Au(III)
complexes were dissolved in DMF, while Ag(I) complexes were
dissolved in DMSO. The highest concentration used was 250 mg
mL1. The inoculums were 105 colony-forming units (cfu mL1)
for bacteria and 104 cfu mL1 for C. albicans. The MIC value
corresponds to the lowest concentration that inhibited the
growth aer 24 h at 37 C. The AgNO3 salt was considered as
positive control, as it has been used clinically.73 To assess the
activity of the compounds in different bacteriological media,
Luria Broth (LB) as well as RPMI-1640 medium supplemented
with LB (5%, v/v) were utilized.45
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay.74 The assay was
carried out using human lung broblasts (MRC5) aer 48 h of
cell incubation in the medium, containing compounds at
concentrations ranging from 0.1 to 100 mg mL1. The MRC5 cell
line was maintained in RPMI-1640 medium supplemented with
100 mg mL1 streptomycin, 100 U mL1 penicillin and 10% (v/v)
fetal bovine serum (FBS) (all from Sigma, Munich, Germany) as
a monolayer (1  104 cells per well) and grown in humidied
atmosphere of 95% air and 5% CO2 at 37 C. The extent of MTT
reduction was measured spectrophotometrically at 540 nm
using a Tecan Innite 200 Pro multiplate reader (Tecan Group
Ltd., Männedorf, Switzerland), and the cell survival was
expressed as percentage of the control (untreated cells). The
percentage viability values were plotted against the log of
concentration and a sigmoidal dose response curve was calcu-
lated by non-linear regression analysis, using the Graphpad
Prism soware, version 5.0 for Windows (Graphpad Soware,
CA, USA). Cytotoxicity is expressed as the concentration of the
compound inhibiting growth by 50% (IC50).
Disruption of P. aeruginosa biolms. Biolm quantication
assays were performed in microtiter plate format using a crystal
violet staining of adherent cells.75 Biolm disruption assay was
performed in 24-well microtiter plate as previously described.76
P. aeruginosa cultures were grown overnight in M9 medium at
37 C with shaking at 180 rpm and subcultured in 24-well
microtiter plate (1% v/v inoculums in 1.0 mL M9 medium
supplemented with 20 mM glucose) and further incubated at 37
C with 180 rpm shaking. Test compounds were added at
concentration of determined MIC value aer 6 h of growth.
Aer 1 h planktonic cells were removed, wells washed with PBS
and adherent cells were stained with crystal violet.
Live/dead staining of the bacterial biolms. To study the
effect of gold(III) and silver(I) complexes on P. aeruginosa PAO1
biolms, overnight bacterial culture grown in LB medium was
diluted to optical density OD600 of 0.05 in M9 medium and the
biolms were grown on glass cover slips in the presence of
selected metal complexes or their mixtures or solvent vehicle.
Aer 24 h growth at 37 C, biolms were washed with 0.9% (w/v)
NaCl and stained with 2.5 mM SYTO9 green uorescent dye and
2.5 mM propidium iodide (PI) red uorescent dye of Live/Dead
staining kit (LIVE/DEAD® BacLight™ Bacterial Viability Kit,This journal is © The Royal Society of Chemistry 2016Thermo Fisher Scientic, Waltham, MA, USA). Biolms and
cells were observed under a uorescence microscope (Olympus
BX51, Applied Imaging Corp., San Jose, USA) at 1000
magnication.
Synergy testing. Complexes Au1 and Au3, as well as Ag1 were
selected for synergy testing aer reviewing individual MIC and
IC50 concentrations using previously described checkerboard
microdilution method.77 Briey, the broth microdilution plates
were inoculated with P. aeruginosa PAO1 to yield the appropriate
density (105 cfu mL1) in 100 mL LB broth and incubated for 24
h at 37 C. One well with no antibiotic was used as a positive
growth control on each plate. Plates were read for visual
turbidity and spectrophotometrically at 600 nm, and results
were recorded aer 24 h of incubation at 37 C as turbidity in
wells indicated growth of the microorganism. The MIC was
determined in the microtiter plate with the lowest drug
concentration at which there was no visible growth. TheMICs of
single drugs A and B (MICA and MICB) and in combination
(MICAB) were determined aer 24 h of incubation at 37 C.
MICAB was dened as the MIC of drug A in the presence of
drug B.
The fractional inhibitory concentration index (FICI) was
calculated for each complex in each combination by using the
following formula: FICA + FICB ¼ FICI, where FICA equals the
MIC of drug A in combination divided by the MIC of drug A
alone and FICB equals the MIC of drug B in combination
divided by the MIC of drug B alone. The FICIs were interpreted
as follows: synergy, FICI of #0.5; #1; additivity or no interac-
tion, FICI of >1 to #2; antagonism, FICI of >4.
In vitro DNA interaction by gel electrophoresis assay
Genomic DNA (gDNA) from P. aeruginosa PAO1 was puried
with a DNeasy tissue kit (Qiagen, Hilden, Germany). The quality
and the concentration of DNA were estimated by measuring UV
absorbance with a NanoVue Plus spectrophotometer (GE
Healthcare, Freiburg, Germany). The ability of Au1–5 and Ag1–5
to bind gDNA from P. aeruginosa PAO1 was examined by using
agarose gel electrophoresis.50,78 For the gel electrophoresis
experiments, gDNA (500 ng) was treated with the investigated
compounds (25 mg mL1) in phosphate buffer (pH 7.4), and the
contents were incubated for 12 h at 37 C, then subjected to gel
electrophoresis on 0.8% (w/v) agarose gel containing 0.1 mg
mL1 of ethidium bromide in TAE buffer (40 mM Tris acetate/1
mM EDTA, pH 7.4) buffer at 60 V for 2 h. Gels were visualized
and analyzed using the Gel Doc EZ system (Bio-Rad, Life
Sciences, Hercules, USA), equipped with the Image Lab™
Soware.
Molecular docking
The geometry optimization of gold(III) and silver(I) complexes
has been carried out with the application of semi-empirical
quantum chemistry method (PM6),79,80 because of its excellent
compromise between computational time and description of
electronic correlation.58 Semi-empirical level of theory was
successfully applied to metal complexes geometry optimization



















































View Article Onlinewith the Gaussian 09 soware package.83 As a model to study
the interaction between the silver(I) and gold(III) complexes and
DNA, the structure of B-DNA dodecamer (CGCGAATTCGCG)2
(PDB:1BNA) was used.84,85 The investigated complexes were
docked into the rigid DNA structure using the Molegro Virtual
Docker (MVD v. 2013.6.0.1.).86 MVD has been successfully
applied in the docking studies of silver(I) and gold(III) complexes
in DNA.87,88 Hydrogen bonds, hydrophilic and hydrophobic
interactions between gold(III) and silver(I) complexes and DNA
were calculated. The binding site was computed with a grid
resolution of 0.3 Å. The MolDock SE as a search algorithm was
used with the number of runs set to 100. The parameters of
docking procedure were: population size 50, maximum number
of iterations 1500, energy threshold 100.00 and maximum
number of steps 300. The number of generated poses was 5. The
estimation of gold(III) and silver(I) complexes and DNA inter-
actions was described by the MVD-related scoring functions:
MolDock score, docking score, Rerank score, Hbond score, van
der Waals (vdW) score, steric interactions, vdW, Hbond and
NonHBond interaction with DNA and ligand efficiency (LE). A
maximum population of 100 and maximum iterations of 10 000
were used for each run and the 5 best poses were retained.
Visualization of the docked pose has been done by using
CHIMERA (http://www.cgl.ucsf.edu/chimera/) molecular
graphics program.In vivo zebrash toxicity assay
Adult zebrash (Danio rerio, wild type) were maintained in the
sh medium (2 mM CaCl2, 0.5 mM MgSO4, 0.7 mM NaHCO3,
0.07 mM KCl) at 27  1 C and 14 h light/10 h dark cycle, and
regularly fed twice daily with commercially dry ake food sup-
plemented with Artemia nauplii (TetraMin™ akes; Tetra Melle,
Germany). Embryos were treated at 4 hours post fertilization
(hpf) with four different concentrations (5, 10, 25 and 50 mg
mL1), and 0.1% DMF and DMSOwere used as negative control.
Embryos were then transferred into 24-well plates containing
1000 mL test solution, 8 embryos per well (24 embryos per
concentration), and incubated at 28 C.
Apical endpoints (Table S3†) used for toxicity evaluation
were recorded at 24, 48, 72, 96 and 114 hpf using an inverted
microscope (CKX41; Olympus, Tokyo, Japan). At 114 hpf, the
embryos were anesthetized by addition of 0.1% (w/v) tricaine
solution (Sigma-Aldrich, St. Louis, MO), photographed and
killed by freezing at 20 C for $24 h.
All experiments involving zebrash were performed in
compliance with the European directive 86/609/EEC and the
ethical guidelines of the Guide for Care and Use of Laboratory
Animals of the Institute for Molecular Genetics and Genetic
Engineering, University of Belgrade.Conclusions
In this study, ve gold(III) complexes Au1–5 and ve silver(I)
complexes Ag1–5 with the aromatic nitrogen-containing
heterocycles, pyridazine (pydz), pyrimidine (pm), pyrazine
(pz), quinoxaline (qx) and phenazine (phz), have been13204 | RSC Adv., 2016, 6, 13193–13206synthesized and structurally characterized by using different
spectroscopic techniques. All investigated gold(III) complexes
are mononuclear and have square-planar geometry, while the
corresponding silver(I) complexes are polynuclear and adopt
different geometries. The investigation of the air/light stability
of the solutions of Au1–5 and Ag1–5 complexes show that the
gold(III) complexes are substantially more stable than the sil-
ver(I) analogues. The obtained results of biological evaluation
reveal that Ag1–5 complexes manifested better activity against
different bacterial strains and the fungus C. albicans than that
of Au1–5 complexes. On the other hand, Au1–5 complexes
exhibited much lower negative effects on the viability of the
normal human lung broblast cell line MRC5 in comparison to
Ag1–5 complexes, which is a desirable property for application
of these compounds as antimicrobial agents. For both of the
metal complexes, it can be concluded that the antimicrobial
and cytotoxic activity depends on the number of aromatic rings
in the N-heterocyclic ligands. Moreover, using combination
approach, we conrmed the synergies of silver(I) and gold(III)
complexes, i.e. the obtained data clearly demonstrated that Au1/
Ag1 8 : 1 and Au3/Ag1 6.4 : 1 mixtures had higher antimicrobial,
P. aeruginosa PAO1 biolm-disruption activity and improved
safety toward human broblast and zebrash embryos than the
tested single complexes. This synergistic effect of gold(III) and
silver(I) complexes with the aromatic N-heterocycles can be
further exploited for the design of novel therapeutic agents with
the improved biological/pharmacological proles.Acknowledgements
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greatly acknowledges Dr Željko Vitnik (Department of Chem-
istry, IChTM – Institute of Chemistry, Technology and Metal-
lurgy, University of Belgrade, Belgrade, Serbia) for providing the
G09 and computing facilities.Notes and references
1 D. Gaynor and D. M. Griffith, Dalton Trans., 2012, 41, 13239–
13257.
2 C. F. Shaw, in Encyclopedia of Inorganic and Bioinorganic
Chemistry, John Wiley & Sons, Ltd, 2011.
3 S. Medici, M. Peana, V. M. Nurchi, J. I. Lachowicz,
G. Crisponi and M. A. Zoroddu, Coord. Chem. Rev., 2015,
284, 329–350.
4 K. D. Mjos and C. Orvig, Chem. Rev., 2014, 114, 4540–4563.
5 F. Bertolini, V. P. Sukhatme and G. Bouche, Nat. Rev. Clin.
Oncol., 2015, 12, 732–742.
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18 B. Đ. Glǐsić, L. Senerovic, P. Comba, H. Wadepohl,
A. Veselinovic, D. R. Milivojevic, M. I. Djuran and
J. Nikodinovic-Runic, J. Inorg. Biochem., 2016, 155, 115–128.
19 L. Ortego, J. Gonzalo-Asensio, A. Laguna, M. D. Villacampa
and M. C. Gimeno, J. Inorg. Biochem., 2015, 146, 19–27.
20 M. Sullivan, A. F.-A. Kia, M. Long, M. Walsh, K. Kavanagh,
S. McClean and B. S. Creaven, Polyhedron, 2014, 67, 549–559.
21 C. Kaes, A. Katz and M. W. Hosseini, Chem. Rev., 2000, 100,
3553–3590.
22 P. J. Steel, Coord. Chem. Rev., 1990, 106, 227–265.
23 C. J. Sumby, Coord. Chem. Rev., 2011, 255, 1937–1967.
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Trans., 2006, 2542–2550.
27 L. Carlucci, G. Ciani, D. M. Proserpio and A. Sironi, Inorg.
Chem., 1998, 37, 5941–5943.
28 M. Munakata, S. Kitagawa, N. Ujimaru, M. Nakamura,
M.Maekawa andH.Matsuda, Inorg. Chem., 1993, 32, 826–832.
29 C. V. K. Sharma and R. D. Rogers, Cryst. Eng., 1998, 1, 19–38.
30 R. G. Vranka and E. L. Amma, Inorg. Chem., 1966, 5, 1020–
1025.
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